United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHRFree Report) by 1.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,248 shares of the biotechnology company’s stock after buying an additional 957 shares during the period. California State Teachers Retirement System owned approximately 0.16% of United Therapeutics worth $16,107,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in UTHR. Jump Financial LLC acquired a new stake in shares of United Therapeutics during the third quarter worth $251,000. J.P. Morgan Private Wealth Advisors LLC lifted its stake in shares of United Therapeutics by 6.1% during the third quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company’s stock worth $288,000 after buying an additional 73 shares during the period. Janney Montgomery Scott LLC lifted its stake in shares of United Therapeutics by 17.0% during the third quarter. Janney Montgomery Scott LLC now owns 8,809 shares of the biotechnology company’s stock worth $1,990,000 after buying an additional 1,279 shares during the period. Burney Co. lifted its stake in shares of United Therapeutics by 3.1% during the third quarter. Burney Co. now owns 9,964 shares of the biotechnology company’s stock worth $2,251,000 after buying an additional 300 shares during the period. Finally, Van ECK Associates Corp lifted its stake in shares of United Therapeutics by 0.9% during the third quarter. Van ECK Associates Corp now owns 9,685 shares of the biotechnology company’s stock worth $2,188,000 after buying an additional 84 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $272.48, for a total transaction of $980,928.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $35,422.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Martine A. Rothblatt sold 1,468 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $275.85, for a total transaction of $404,947.80. Following the completion of the sale, the director now owns 130 shares of the company’s stock, valued at approximately $35,860.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $272.48, for a total transaction of $980,928.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $35,422.40. The disclosure for this sale can be found here. Insiders sold 164,328 shares of company stock valued at $40,002,673 over the last 90 days. Corporate insiders own 12.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on UTHR shares. The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. HC Wainwright restated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research report on Thursday, May 2nd. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. Finally, Oppenheimer boosted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $309.44.

Get Our Latest Report on United Therapeutics

United Therapeutics Stock Down 0.1 %

UTHR opened at $276.40 on Friday. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $280.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The company has a fifty day moving average of $253.45 and a two-hundred day moving average of $236.90. The stock has a market capitalization of $12.26 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 4.12 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.86 earnings per share. On average, research analysts expect that United Therapeutics Co. will post 24.61 earnings per share for the current year.

United Therapeutics Company Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.